• info@heparegenix.com
  • +49 (0)7071 7912810
  • Sitemap
  • Site Notice
  • Privacy Policy
HepaRegeniX GmbH
  • Home
  • About us
  • Investors
  • Science
    • Liver diseases face an enormous unmet medical need
    • MKK4 – A First-in-class Therapeutic Target
    • Translation into the Clinic
  • Jobs
  • News
  • Contact
Search
  • Home
  • About us
  • Investors
  • Science
    • Liver diseases face an enormous unmet medical need
    • MKK4 – A First-in-class Therapeutic Target
    • Translation into the Clinic
  • Jobs
  • News
  • Contact

HepaRegeniX appoints Dr. Andreas Busch as Senior Advisor

p3889712022-11-23T10:05:06+01:00

Dr. Busch will help the Company to further advance the development of MKK4 inhibition, a first-in-class treatment paradigm for liver resection and transplant.

11/23/2022
By p3889712022, Press releaseComments Off
Read more...

HepaRegeniX reports positive topline results of its Phase 1 Clinical Trial of HRX-0215, a First-In-Class MKK4 inhibitor

p3889712022-05-12T10:21:20+02:00

HRX-0215 proved to be safe and well tolerated in healthy volunteers.

05/12/2022
By p3889712022, Press releaseComments Off
Read more...

HepaRegeniX appoints Elias Papatheodorou as new Chairman of the Board of Directors

p3889712022-03-30T11:52:14+02:00

He follows Dr. Graham Dixon who served as Chairman on the Board of HeparegeniX since 2017.

03/30/2022
By p3889712022, Press releaseComments Off
Read more...

HepaRegeniX to present key results on MKK4 inhibitors and their therapeutic efficacy at upcoming scientific conferences

p3889712021-12-29T10:46:15+01:00

New data supporting therapeutic potential of MKK4 inhibition in advanced liver diseases.

11/04/2021
By p3889712021, Press releaseComments Off
Read more...

HepaRegeniX initiates a preclinical collaboration with the Netherlands Cancer Institute

p3889712021-12-29T10:47:53+01:00

HepaRegeniX initiates a preclinical collaboration with the Netherlands Cancer Institute to explore the potential of its 2nd MKK4 inhibitor HRX-0233 for use in cancer combination therapy.

10/20/2021
By p3889712021, Press releaseComments Off
Read more...

HepaRegeniX initiates first-in-man Phase 1 trial for its lead MKK4 inhibitor HRX‑0215

p3889712021-12-29T10:37:24+01:00

HRX-0215 is the first compound from the company´s small molecule-based drug discovery platform ready for clinical testing.

08/10/2021
By p3889712021, Press releaseComments Off
Read more...

HepaRegeniX achieves further milestone related to proof of safety and efficacy for MKK4 inhibition in an advanced chronic liver disease model

p3889712021-12-29T11:07:01+01:00

New preclinical data indicate beneficial therapeutic effects in non-alcoholic steatohepatitis (NASH)-associated liver carcinomas.

12/03/2020
By p3889712020, Press releaseComments Off
Read more...

HepaRegeniX hires industry expert Dr. Markus Weissbach as Senior Clinical Advisor

p3889712021-12-29T11:14:10+01:00

30 years of specialist knowledge in clinical operations to translate encouraging preclinical results into the clinic.

11/18/2020
By p3889712020, Press releaseComments Off
Read more...

HepaRegeniX GmbH to deliver an oral presentation of preclinical results on MKK4 inhibition in liver regeneration at The Liver Meeting® 2020

p3889712021-12-29T11:15:52+01:00

Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models...

11/10/2020
By p3889712020, Press releaseComments Off
Read more...

HepaRegeniX GmbH hires industry veteran Dr David Shapiro as Senior Medical Advisor

p3889712021-12-29T11:21:56+01:00

Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models...

10/20/2020
By p3889712020, Press releaseComments Off
Read more...
12Next  
Get In Touch
HepaRegeniX GmbH: Logo

HepaRegeniX has successfully discovered and developed several drug candidates to combat multiple liver diseases. The first candidate HRX-0215 has recently entered clinical development.

Get in touch

Phone: +49 (0)7071 7912810
Fax: +49 (0)7071 7912809
E-mail: info@heparegenix.com

Address

HepaRegeniX GmbH
Eisenbahnstraße 63
72072 Tübingen
Germany

© Copyright 2016-2020 HepaRegeniX GmbH. All Rights Reserved.